期刊
BEHAVIOURAL PHARMACOLOGY
卷 22, 期 4, 页码 291-299出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/FBP.0b013e328347546d
关键词
depression; forced-swim test; mouse; nicotinic acetylcholine receptors; novelty-suppressed feeding; partial agonists; tail-suspension test
资金
- National Institute of Mental Health [MH077681]
- National Institute on Drug Abuse [DA00436]
- Pfizer
Previous studies have suggested that treatment with antagonists or partial agonists of nicotinic acetylcholine receptors containing the beta 2-subunit (beta 2* nAChRs) results in antidepressant-like effects. In this study, we tested three novel compounds with different affinity and functional efficacy at alpha 4 beta 2* nAChRs, which were synthesized as part of nAChR discovery projects at Pfizer, in the tail-suspension, forced-swim, and novelty-suppressed feeding tests of antidepressant efficacy. All compounds tested reduced immobility in the forced-swim test and one of the compounds also reduced immobility in the tail-suspension test. All the compounds appeared to affect food intake on their own, with two compounds reducing feeding significantly in the home cage, precluding a clear interpretation of the results in the novelty-suppressed feeding test. None of the compounds altered locomotor activity at the doses and time points used here. Therefore, a subset of these compounds has pharmacological and behavioral properties that demonstrate the potential of nicotinic compounds as a treatment of mood disorders. Further development of nicotinic-based antidepressants should focus on increasing nAChR subtype selectivity to obtain consistent antidepressant properties with an acceptable side-effect profile. Behavioural Pharmacology 22: 291-299 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据